For millions who suffer from the debilitating pain of migraines, a future with significantly reduced suffering may be on the horizon. A leading neurologist believes that whereas a complete cure remains elusive, advancements in treatment could drastically reduce the number of patients for whom migraines are untreatable – potentially dropping the figure to as low as 2% of sufferers in the UK.
Professor Fayyaz Ahmed, 65, has dedicated nearly three decades to advancing research and treatment for headaches and migraines. His pioneering work includes establishing the UK’s first dedicated NHS clinic utilizing Botox injections for migraine treatment, where he has treated over 5,000 patients since its opening in Hull in 2012. Ahmed, who recently published a book detailing his career, suggests that a new generation of drugs holds the key to improving outcomes for those who haven’t responded to current medications.
Migraines affect approximately six million people in the UK, according to the NHS. Unlike typical headaches, migraines are often accompanied by a range of symptoms including dizziness, sensitivity to light, visual disturbances, nausea, vomiting, and difficulty speaking. The pain, frequently described as throbbing, can be localized to one side of the head and can persist for several days.
Current treatments, such as Botox and medications targeting calcitonin gene-related peptide (CGRP) – a chemical in the brain involved in pain transmission – have already proven effective for around 95% of patients, according to Ahmed. “In my lifetime see any cure coming out given that we still don’t know what causes migraines,” he stated. However, he believes emerging drugs, currently under development in Denmark, could further reduce the proportion of those who find no relief.
Ahmed’s work extends beyond clinical practice. He is an ambassador for The Migraine Trust, an honorary advisor with the British Association for the Study of Headache, and a trustee of both the International Headache Society and the Migraine Trust. He likewise served as Chair of Headache UK from 2012-2016.
Establishing the UK’s first dedicated NHS Botox clinic wasn’t without its challenges. Ahmed recalls facing skepticism when he initially proposed the idea. “I wanted to be the first one to set up a clinic for the benefit of the patients and I managed to do that and that is, I feel, quite a large achievement for me,” he said. Now, 14 years later, his focus has shifted towards mentoring the next generation of doctors.
To further support research, Ahmed is raising funds through the sale of his memoir, “Beneath the Dust,” which chronicles his journey from childhood in Pakistan to his medical career in the UK. Proceeds from the book will be donated to The Migraine Trust to fund PhD research. He finds immense satisfaction in the positive feedback he receives from patients, noting that it reinforces the impact of his work on their wellbeing.
While the precise causes of migraines remain unknown, research suggests factors like hormonal fluctuations – particularly estrogen – and genetic predisposition play a significant role, according to Ahmed. The Migraine Trust also notes that the condition is two to three times more common in women than men.
Looking ahead, the development of these new drugs offers a promising avenue for improving the lives of migraine sufferers. Continued research into the underlying causes of migraines remains crucial, but the potential to significantly reduce the number of untreatable cases represents a substantial step forward.
What are your thoughts on these potential advancements in migraine treatment? Share your experiences and perspectives in the comments below.
Disclaimer: This article provides informational content about health and medicine and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider for any questions you may have regarding a medical condition.
